Reply to "Onset of epidermolysis bullosa acquisita under therapy with ustekinumab for the treatment of Crohn disease" by Gambichler et al.
Sign Up to like & getrecommendations! Published in 2023 at "Clinical and experimental dermatology"
DOI: 10.1093/ced/llad118
Abstract: Response to “Onset of epidermolysis bullosa acquisita under therapy with ustekinumab for the treatment of Crohn disease” read more here.
Keywords: bullosa acquisita; acquisita therapy; epidermolysis bullosa; ustekinumab treatment ... See more keywords
Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison.
Sign Up to like & getrecommendations! Published in 2020 at "Rheumatology"
DOI: 10.1093/rheumatology/keaa710
Abstract: OBJECTIVES To evaluate the characteristics of patients (pts) with PsA treated by ustekinumab (UST) or secukinumab (SEK) and to compare real-world persistence of UST and SEK in PsA. METHODS In this retrospective, national, multicentre cohort… read more here.
Keywords: secukinumab ustekinumab; sek; sek ust; ustekinumab treatment ... See more keywords
Ustekinumab in the treatment of acute disseminated pyoderma gangrenosum in a patient with Crohn’s disease
Sign Up to like & getrecommendations! Published in 2023 at "Dermatology Reports"
DOI: 10.4081/dr.2023.9630
Abstract: Pyoderma gangrenosum (PG) is an auto-inflammatory dermatosis characterized by lesions that often cause ulcers. We present a case of successful ustekinumab treatment for acute general PG in a 31-year-old woman with coexisting Crohn's disease (CD).… read more here.
Keywords: pyoderma gangrenosum; crohn disease; ustekinumab treatment; patient ... See more keywords